Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Triple Negative Breast Neoplasms 7 Breast Neoplasms 6 Lung Neoplasms 5 Ovarian Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Neoplasms 2 Medulloblastoma 2 Fallopian Tube Neoplasms 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Thymic epithelial tumor 1 Thrombocythemia, Essential 1 Stage IIIB or IV Non-Small Cell Lung Cancer 1 Squamous NSCLC 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Retinoblastoma 1 Recurrence 1 Primary Myelofibrosis 1 Primary Malignant Neoplasm of Ovary 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Rituximab 2 loncastuximab tesirine 1 etoposide phosphate 1 blinatumomab 1 Tubercidin 1 Immunotherapy, Adoptive 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, B-Cell × Carboplatin × Clear all

NCT05991388 2026-02-20

Glo-BNHL

University of Birmingham

Phase 2/3 Recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡